Bioorganic & Medicinal Chemistry Letters 2006-07-15

Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.

Lihu Yang, Changyou Zhou, Liangqin Guo, Gregori Morriello, Gabor Butora, Alexander Pasternak, William H Parsons, Sander G Mills, Malcolm MacCoss, Pasquale P Vicario, Hans Zweerink, Julia M Ayala, Shefali Goyal, William A Hanlon, Margaret A Cascieri, Marty S Springer

文献索引：Bioorg. Med. Chem. Lett. 16(14) , 3735-9, (2006)

全文：HTML全文

摘要

Systematic modification of a screening lead yielded a class of potent glycinamide based CCR2 antagonists. The best compound (55, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-{[2-(1-piperidinyl)ethyl]amino}-2-(3-thienyl)acetamide) displayed good binding affinity (IC50=30 and 39 nM) toward human monocytes and CHO cell expressing human CCR2b, respectively. Functionally, it blocked MCP-1 (CCL2)-induced calcium mobilization (IC50=50 nM) and chemotaxis mediated through the CCR2 receptor (9.6 nM). It is selective against other chemokine receptors tested.